Paradigm Biopharmaceuticals Ltd traded at 0.32 this Tuesday February 3rd, increasing 0.02 or 6.78 percent since the previous trading session. Looking back, over the last four weeks, Paradigm Biopharmaceuticals gained 14.86 percent. Over the last 12 months, its price fell by 43.24 percent. Looking ahead, we forecast Paradigm Biopharmaceuticals Ltd to be priced at 0.30 by the end of this quarter and at 0.28 in one year, according to Trading Economics global macro models projections and analysts expectations.
Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).